Gunderson Dettmer’s life sciences practice is one of the firm’s most active practice areas.

The firm’s clients include venture-backed and public life sciences companies and venture capital firms headquartered around the world. They are served by a team of more than 50 lawyers, with special concentration in Boston, San Diego, Silicon Valley and Ann Arbor.

The firm’s life science company clients represent a broad spectrum of technologies, from medical devices and diagnostics to therapeutics and healthcare IT. Our representation typically spans the full lifecycle of the company, from incorporation through venture capital and growth equity financings, in-licenses, bet-the-company strategic collaborations, day-to-day commercial contract issues, and exit activities, including M&As and IPOs. In addition to its robust company-side practice, the firm also represents many of the pre-eminent life sciences-focused investment funds in both their fund formations as well as in their investment activities.

The firm also represented ARMO Biosciences in its $1.6 billion acquisition by Eli Lilly, which was named a Finance & Transactional Impact Deal of the Year by LMG Life Sciences.